Wang X - Search Results

1

Prophylaxis against hepatitis E: at risk populations and human vaccines.

Wang X, Li M, Li S, Wu T, Zhang J, Xia N, Zhao Q. Wang X, et al. Expert Rev Vaccines. 2016 Jul;15(7):815-27. doi: 10.1586/14760584.2016.1143365. Epub 2016 Feb 5. Expert Rev Vaccines. 2016. PMID: 26775537 Free article. Review.

2

Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.

Zhang X, Wei M, Sun G, Wang X, Li M, Lin Z, Li Z, Li Y, Fang M, Zhang J, Li S, Xia N, Zhao Q. Zhang X, et al. Among authors: wang x. Vaccine. 2016 Nov 21;34(48):5871-5877. doi: 10.1016/j.vaccine.2016.10.045. Epub 2016 Oct 25. Vaccine. 2016. PMID: 27793484

3

Calcium phosphate nanoparticles as a new generation vaccine adjuvant.

Lin Y, Wang X, Huang X, Zhang J, Xia N, Zhao Q. Lin Y, et al. Among authors: wang x. Expert Rev Vaccines. 2017 Sep;16(9):895-906. doi: 10.1080/14760584.2017.1355733. Epub 2017 Jul 25. Expert Rev Vaccines. 2017. PMID: 28712326 Free article. Review.

4

Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine.

Wang X, Li M, Lin Z, Pan H, Tang Z, Zheng Z, Li S, Zhang J, Xia N, Zhao Q. Wang X, et al. Vaccine. 2018 Nov 29;36(50):7650-7658. doi: 10.1016/j.vaccine.2018.10.089. Epub 2018 Nov 2. Vaccine. 2018. PMID: 30396752

5

Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods.

Yin X, Wang X, Zhang Z, Li Y, Lin Z, Pan H, Gu Y, Li S, Zhang J, Xia N, Zhao Q. Yin X, et al. Among authors: wang x. J Pharm Biomed Anal. 2020 Jan 5;177:112880. doi: 10.1016/j.jpba.2019.112880. Epub 2019 Sep 13. J Pharm Biomed Anal. 2020. PMID: 31546137

6

Detection of subtle differences in analogous viral capsid proteins by allowing unrestricted specific interaction in solution competition ELISA.

Cao L, Wang X, Fang M, Xia N, Zhao Q. Cao L, et al. Among authors: wang x. J Virol Methods. 2016 Oct;236:1-4. doi: 10.1016/j.jviromet.2016.06.007. Epub 2016 Jun 16. J Virol Methods. 2016. PMID: 27321427

7

Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants.

Li M, Wang X, Cao L, Lin Z, Wei M, Fang M, Li S, Zhang J, Xia N, Zhao Q. Li M, et al. Among authors: wang x. Vaccine. 2016 Aug 17;34(37):4422-8. doi: 10.1016/j.vaccine.2016.07.012. Epub 2016 Jul 15. Vaccine. 2016. PMID: 27426626

8

Escherichia coli-derived virus-like particles in vaccine development.

Huang X, Wang X, Zhang J, Xia N, Zhao Q. Huang X, et al. Among authors: wang x. NPJ Vaccines. 2017 Feb 9;2:3. doi: 10.1038/s41541-017-0006-8. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263864 Free PMC article.

9

Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid.

Zhang C, Huang X, Chen S, Li Y, Li Y, Wang X, Tang J, Xia L, Lin Z, Luo W, Li T, Li S, Zhang J, Xia N, Zhao Q. Zhang C, et al. Among authors: wang x. Vaccine. 2018 Oct 29;36(45):6761-6771. doi: 10.1016/j.vaccine.2018.09.035. Epub 2018 Oct 1. Vaccine. 2018. PMID: 30287156

10

Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal.

Chen S, Huang X, Li Y, Wang X, Pan H, Lin Z, Zheng Q, Li S, Zhang J, Xia N, Zhao Q. Chen S, et al. Among authors: wang x. Eur J Pharm Biopharm. 2019 Aug;141:221-231. doi: 10.1016/j.ejpb.2019.05.027. Epub 2019 May 30. Eur J Pharm Biopharm. 2019. PMID: 31154067

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206,286 results

Search Page

Filters